Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Raquel Serrano Blanch is active.

Publication


Featured researches published by Raquel Serrano Blanch.


Clinical & Translational Oncology | 2005

Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil

Rafael Morales Chamorro; Raquel Serrano Blanch; María José Méndez Vidal; María Auxiliadora Gómez España; María Jesús Rubio Pérez; Juan Rafael de la Haba Rodríguez; Enrique Aranda Aguilar

Pseudomembranous colitis is frequently associated with antibiotics and more rarely with chemotherapeutic agents such as 5-fluorouracil. The objective of this study is to show that it is possible to confuse this infection with chemotherapy associated toxicity. We present a 54 year old woman who underwent surgery for colorectal cancer and in the first cycle of chemotherapy with 5-fluorouracil developed pseudomembranous colitis. We detected the toxin B ofClostridium difficile in stools and we began early antibiotic treatment. Thus, in patients with post chemotherapy neutropenia and diarrhoea that develop negatively, we have to rule out this infection.


American Journal of Clinical Oncology | 2003

Adjuvant treatment in elderly patients with breast cancer: critical review of clinical practice.

Juan Rafael de la Haba Rodríguez; María José Méndez Vidal; Auxiliadora Gómez España; Raquel Serrano Blanch; Antonio Tejera Vaquerizo; Isidoro Carlos Barneto Aranda; Enrique Aranda Aguilar

Today the use of adjuvant treatment of breast cancer is unquestionable in the management of this disease. Both chemotherapy and hormonal therapy have proved to be beneficial, not only with respect to the reduction of the risk of recurrence, but also with respect to mortality. However, in elderly patients, this therapeutic approach is occasionally the subject of controversy, due to the undervaluing of the tumoral disease with respect to the multiple pathology frequently present in these patients. This study analyses a retrospective series of 100 patients more than 70 years old with breast cancer who underwent radical surgery between 1990 and 1998, with an extension study without evidence of metastasis and a minimum follow-up of 2 years. As occurs in the population of this age, in our series 77% of the patients presented with concomitant disease under medical treatment, and although the majority received adjuvant treatment with tamoxifen, the principal cause of death in this series was the breast cancer that had been diagnosed.Today the use of adjuvant treatment of breast cancer is unquestionable in the management of this disease. Both chemotherapy and hormonal therapy have proved to be beneficial, not only with respect to the reduction of the risk of recurrence, but also with respect to mortality. However, in elderly patients, this therapeutic approach is occasionally the subject of controversy, due to the undervaluing of the tumoral disease with respect to the multiple pathology frequently present in these patients. This study analyses a retrospective series of 100 patients more than 70 years old with breast cancer who underwent radical surgery between 1990 and 1998, with an extension study without evidence of metastasis and a minimum follow-up of 2 years. As occurs in the population of this age, in our series 77% of the patients presented with concomitant disease under medical treatment, and although the majority received adjuvant treatment with tamoxifen, the principal cause of death in this series was the breast cancer that had been diagnosed.


European Journal of Cancer Prevention | 2005

Breast cancer screening: another point of view

J. R. De La Haba Rodriguez; Rafael Morales Chamorro; Miquel Vidal; Raquel Serrano Blanch; L. T. Beltran; M. A. Benito; S. G. Cabezas; A. J. Carrasco; Enrique Aranda Aguilar

The breast cancer screening programmes (BCSP) are very controversial at the present time. They are evaluated by different socio-economic sectors, each with its own particular point of view. Large numbers of breast cancer cases are concentrated in the Oncology Services, which are, therefore, sensitive to the changes that these programmes could bring about. All patients attending the medical oncology and radiotherapy services of the Reina Sofia University Hospital, Córdoba from January 1994 until January 2003 were reviewed. Of 1785 patients, 829 went to these services after the start of the BCSP introduced in March 1999 and 956 before it. The variables analysed were age, presentation form, stage and treatment received. In conclusion, the BCSP has produced favourable changes with respect to stage (increasing the percentage of early breast cancer) and therapeutic management (increasing conservative surgery and decreasing the number of adjuvant treatments (radiotherapy and chemotherapy)). These changes are more outstanding in the population group covered by the BCSP.


Clinical & Translational Oncology | 2004

Reactivación del virus de la hepatitis B en paciente oncológico tras tratamiento con quimioterapia: hepatitis fulminante

Rafael Morales Chamorro; Juan Rafael de la Haba Rodríguez; Raquel Serrano Blanch; María José Méndez Vidal; Isidoro Carlos Barneto Aranda; Enrique Aranda Aguilar

Re-activation of the hepatitis B virus is very unusual, but has been described as a complication of chemotherapy. Most reported cases are related to haematological malignancies and, occasionally, to solid tumours.We report a case of hepatitis B virus re-activation resulting in fulminant hepatitis in a patient with non-small-cell lung cancer following chemotherapy with cisplatin and gemcitabine.Risk-factors associated with the re-activation were gender, age and the administration of cortico-steroids.During chemotherapy administered to patients with a history of chronic hepatitis B, care must be taken to avoid the administration of cortico-steroids as anti-emetics, and to monitor the patients transaminase concentrations.


Archive | 2015

HEREDITARY CANCER IN WOMEN EL CÁNCER HEREDITARIO EN MUJERES

Rafael Morales Chamorro; Isabel Chirivella González; Gemma Llort Pursals; Ana Beatriz Sánchez Heras; Raquel Serrano Blanch; Alexandre Teule Vega; Carmen Guillén Ponce; Begoña Graña Suárez


Arbor-ciencia Pensamiento Y Cultura | 2015

El cáncer hereditario en mujeres

Rafael Morales Chamorro; Isabel Chirivella González; Gemma Llort Pursals; Ana Beatriz Sánchez Heras; Raquel Serrano Blanch; Alexandre Teule Vega; Carmen Guillén Ponce; Begoña Graña Suárez


Clinical & Translational Oncology | 2010

TTD consensus document on the diagnosis and management of hereditary colorectal cancer

Pedro Pérez Segura; C. Alonso; Teresa Ramón y Cajal; Raquel Serrano Blanch; Enrique Aranda


Clinical & Translational Oncology | 2010

Erratum to: TTD consensus document on the diagnosis and management of hereditary colorectal cancer

Pedro Pérez Segura; C. Alonso; Teresa Ramón y Cajal; Raquel Serrano Blanch; Enrique Aranda


Revisiones en cáncer | 2007

Estadificación del cáncer de esófago

M. A. Gómez España; Raquel Serrano Blanch; Enrique Aranda Aguilar


Revisiones en cáncer | 2005

Carcinoma de páncreas.Factores pronósticos

M. A. Gómez España; Raquel Serrano Blanch; Enrique Aranda Aguilar

Collaboration


Dive into the Raquel Serrano Blanch's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Alonso

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Teresa Ramón y Cajal

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Enrique Aranda

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Miquel Vidal

Barcelona Supercomputing Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge